# Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

> **NCT01400412** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 262 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** Tenofovir disoproxil fumarate
- **DRUG:** Emtricitabine
- **DRUG:** Placebo for Tenofovir disoproxil fumarate
- **DRUG:** Placebo for Maraviroc
- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT01400412
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01-17
- **Primary completion:** 2014-06-30
- **Final completion:** 2014-06-30
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400412, "Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01400412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*